03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
18:06 , May 15, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Mouse studies suggest nanoparticles loaded with an ADORA2A antagonist and conjugated to CAR T cells could help treat ovarian cancer. The conjugate consists of cross-linked multilamellar liposomal nanoparticles loaded with a tool...
02:46 , Mar 24, 2018 |  BioCentury  |  Product Development

Optimism for A2A

Once considered solely a neurology target, the adenosine pathway has attracted interest in immuno-oncology based on its ability to control whether immune cells adopt a stimulatory or suppressive phenotype. The early results from A2A receptor...
23:10 , Oct 6, 2017 |  BioCentury  |  Finance

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
12:29 , May 26, 2017 |  BC Week In Review  |  Company News

Corvus and Genentech expand 2015 deal, add second combo trial

Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) said the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) will manage a Phase Ib/II trial evaluating Corvus’ CPI-444 in combination with Genentech’s Tecentriq atezolizumab in non-small cell lung cancer (NSCLC) patients...
18:48 , May 12, 2017 |  BC Week In Review  |  Company News

Monash grants Corvus rights to undisclosed immuno-oncology program

Monash University (Clayton, Australia) granted Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) worldwide rights to an undisclosed immuno-oncology program, which includes a lead product candidate. Corvus said it plans to develop candidates from the program as monotherapies and...
04:43 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

CPI-444: Additional Ph I/Ib data

Data from 96 evaluable solid tumor patients in the second part of an open-label, international Phase I/Ib trial showed that twice-daily 100 mg oral CPI-444 alone and in combination with Tecentriq atezolizumab for 28 days...
20:47 , Apr 5, 2017 |  BC Extra  |  Clinical News

Corvus slammed after solid tumor study shows few responses

Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) failed to recover on Wednesday after disappointing data from a Phase I/Ib trial of cancer candidate CPI-444 sank the company's share price by nearly half on Tuesday. Corvus lost 50% to...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

CPI-444: Phase I data

Data from 48 solid tumor patients from 4 cohorts in the dose-selection portion of an open-label, international Phase I/Ib trial showed that oral CPI-444 alone and in combination with Tecentriq atezolizumab was well tolerated, with...
07:00 , Apr 25, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/22 cls Chiasma Inc. (NASDAQ:CHMA) Cowen Ritu Baral Downgrade Market perform (from outperform) -62% $3.83 William Blair Tim Lugo Downgrade...